Full-Time

Associate Director

Patient Marketing

Blueprint Medicines

Blueprint Medicines

501-1,000 employees

Biopharma developing kinase inhibitors for cancer

Compensation Overview

$190k - $240k/yr

+ Bonus + 401(k) Match

Cambridge, MA, USA

In Person

Up to 25% travel within the United States.

Bachelor's, MBA

Category
Growth & Marketing (2)
,
Required Skills
Marketing

Get referred to Blueprint Medicines

See people who can refer or advise you

Requirements
  • BA/BS degree required
  • Minimum of 6 years of experience in the biotech/pharmaceutical industry, including direct involvement in marketing, sales, or market development activities
  • Previous in-line marketing experience a must
  • Required travel: Up to 25%
Responsibilities
  • Lead the development and stewardship of the branded patient journey, including messaging strategy and overall experience design across patient-facing touchpoints, ensuring alignment with the overall consumer strategy and AYVAKIT core narrative
  • Own the development and execution of core branded initiatives, including campaigns, patient materials and onboarding experiences, ensuring alignment to the patient journey strategy and business objectives
  • Define branded success metrics and translate insights and performance data into strategic decisions, driving ongoing optimization and measurable business impact
  • Guide branded omnichannel strategy in partnership with omnichannel lead, ensuring consistent messaging, effective activation and impact across key channels
  • Own and evolve the branded messaging architecture, including core claims, and content strategy, ensuring ongoing differentiation, clarity and consistency
  • Identify critical moments and barriers within the patient journey and develop strategies to drive engagement, consideration, and persistence
  • Support the US annual brand planning process, including development of the branded tactical roadmap, ensuring alignment to business priorities and patient strategy
  • Lead agency partners and collaborate closely with internal team members, providing clear direction, feedback, and decision-making to drive high-quality execution and reduce rework
  • Represent branded strategy in cross-functional and leadership settings, clearly articulating rational to drive alignment and accelerate decision making
  • Act as a thought partner in advancing consumer innovation and future growth opportunities, identifying new ways to strengthen engagement and drive business impact
Desired Qualifications
  • Advanced degree, MBA, or other equivalent experience preferred
  • Experience owning patient-facing marketing strategy and execution for pharmaceutical or biotech products in the US; Expertise in branded strategy development, including patient journey design, messaging architecture and campaign development
  • Demonstrated ability to translate patient insights, market research and data into clear strategic direction
  • Experience working within omnichannel environments, ensuring effective pull-through of strategy across digital, media and patient engagement channels
  • Strong understanding of performance measurement and analytics, with the ability to connect marketing activities to patient behavior and business outcomes
  • Demonstrated track record of leading agency partners and driving high-quality strategic and creative output
  • Proven ability to influence without authority and work cross-functionally to align and deliver brand strategy
  • Strong written and communication skills with the ability to clearly articulate strategy and rationale
  • Ability to operate independently in a fast-paced environment, balancing multiple priorities while maintaining strategic clarity
  • Flexibility and the ability to adapt strategy and approach in response to evolving business needs
  • Launch experience and commercialization of new products preferred
  • Motivated by patient focus, urgency and personal commitment to high performance, results and compliance.
  • Commitment to Blueprint Medicines’ Core Values: Patients First, Thoughtfulness, Urgency, Trust, Optimism

Blueprint Medicines develops and commercializes kinase inhibitors for cancer and other diseases. Its lead product, Ayvakit (avapritinib), blocks enzymes that drive tumor growth in gastrointestinal stromal tumors with PDGFRA exon 18 mutations. The company also has a pipeline of other kinase inhibitors in clinical development for lung, breast, and blood cancers, plus preclinical programs in immunology and rare diseases. By performing discovery, development, and commercialization in-house, it aims to bring targeted therapies to patients with unmet medical needs and expand its global oncology portfolio.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2011

Get referred to Blueprint Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi reported €367 million Ayvakit net sales in first-half 2026, validating demand.
  • Blueprint's HARBOR elenestinib study and BLU-808 trials keep generating optionality in 2026.
  • Sanofi's $9.1 billion acquisition funds global commercialization and near-term pipeline development.

What critics are saying

  • Sanofi is cutting 229 Blueprint jobs in Cambridge from October 2026 through June 2027.
  • Two legacy Cambridge offices close, and remaining Blueprint staff relocate to Sanofi's campus.
  • Ayvakit concentration is dangerous; a Sanofi integration miss can erase Blueprint's standalone identity.

What makes Blueprint Medicines unique

  • Ayvakit remains the first approved systemic mastocytosis therapy, protected by rare-disease specialization.
  • Blueprint built deep KIT biology expertise across avapritinib, elenestinib, and BLU-808 programs.
  • Its Cambridge mast-cell franchise uniquely spans oncology and immunology, not generic kinase discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Mental Health Support

Employee Stock Purchase Plan

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
pharmaphorum
Aug 17th, 2026
Sanofi to lay off 229 Blueprint employees, close offices.

Sanofi to lay off 229 Blueprint employees, close offices. Sanofi is laying off 229 former Blueprint Medicines employees in Cambridge, MA and closing two legacy Blueprint facilities. The news comes just over a year after Sanofi's $9 billion acquisition of Blueprint, one of the biggest deals of 2025. Boston Business Journal broke the news, which pharmaphorum has independently verified with the company. "As part of the integration following our acquisition of Blueprint Medicines in July 2025, we made thoughtful organisational decisions to align our structure with our long-term business priorities and the needs of our commercial portfolio and pipeline," Sanofi said in an emailed statement. "These decisions were made carefully to position the organisation for future success while continuing to deliver for patients. Many Blueprint employees are joining Sanofi. Those affected by these decisions have already been informed and we will continue to provide multiple avenues of support through their transitions." Blueprint's facilities at 45 Sidney St and 38 Sidney St in Cambridge are closing, with remaining Blueprint employees reporting to Sanofi's East Cambridge office. Since the acquisition was finalised in July 2025, there's already been an exodus of Blueprint talent at the top levels of the company. All 13 members of Blueprint's leadership team (as listed on their website at the time) have left the company in the last year, with most departing in October of last year, according to LinkedIn. Chief scientific officer Percy Carter has been leading preclinical and translational sciences at Pfizer, chief commercial officer Philina Lee is now CEO at AdvanceCell, R&D president Fouad Namouni is CEO at Synolo Therapeutics, and three separate members of the team - chief medical officer Dr Becker Hewes, chief business officer Sherwin Sattarzadeh, and SVP corporate affairs Jim Baker - have landed in similar roles at Damora Therapeutics, a Boston biotech focused on blood disorders. Sanofi acquired Blueprint to secure the rights to Ayvakit/Ayvakyt (avapritinib), a tyrosine kinase inhibitor (TKI) that targets the KIT D816V mutation in ASM, an umbrella term that covers multiple disorders, including aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm (SM-AHN), and mast cell leukaemia (MCL). Ayvakit is the only approved medicine for ASM, which causes symptoms like itching, fever, abdominal pain, and nausea, and can also lead to organ damage, bone fractures, and anaemia. People with ASM typically have a life expectancy ranging from six months to around three-and-a-half years. According to recent Sanofi financial reports, Aykavit earned the company €367 million in net sales in the first half of 2026. 17 August, 2026

Fusacq
Jun 2nd, 2025
Sanofi Acquires Blueprint Medicines Biotech

Sanofi has acquired the American biotech company Blueprint Medicines, which specializes in systemic mastocytosis, a rare disease characterized by abnormal activation or proliferation of mast cells in tissues, most commonly the skin and bone marrow.

Google
Jun 2nd, 2025
Sanofi Acquires Blueprint for $9.1B

Sanofi is set to acquire Blueprint Medicines for an equity value of $9.1 billion, according to Bloomberg.

Investors Hangout
Jun 2nd, 2025
Sanofi Acquires Blueprint for $9.1B

Sanofi is acquiring Blueprint Medicines for approximately $9.1 billion, enhancing its immunology portfolio. This acquisition includes Ayvakit, the only FDA-approved treatment for systemic mastocytosis, and promising therapies like elenestinib and BLU-808. Sanofi will finance the deal with cash and new debt, expecting it to boost gross margin and operating income post-2026. The merger aligns with Sanofi's strategy to lead in immunology and address rare diseases.

The Gazette
Jun 2nd, 2025
Sanofi to buy US biopharma group Blueprint for up to $9.5 billion

PARIS (Reuters) -France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European healthcare company so far this year, according to LSEG data.